RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Abstract
Lipid accumulation drives the development of atherosclerotic cardiovascular disease, the leading cause of death worldwide. The liver is the primary target for lipid-lowering therapies due to its central role in lipid metabolism. Despite advances in small-molecule drugs, substantial residual cardiovascular risk remains. Recent clinical evidence in 2026 reaffirms the “lower is better” paradigm, showing that achieving very low low-density lipoprotein cholesterol (
Fields of Study & Subjects
Fatty Acid Research and Health
RNA Interference and Gene Delivery
Lipid metabolism and disorders
Publication details
- Journal / source
- Research
- Publisher
- American Association for the Advancement of Science (AAAS)
- Volume
- 9
- Pages
- 1288–1288
- Publication date
- 1 January 2026
- Language
- EN